Cumbre IP Ventures, L.P.
Records under this name other than patents Cumbre IP Ventures, L.P. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Cumbre IP Ventures, L.P.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,678,791 | Nitroheteroaryl-containing rifamycin derivatives Formerly held In force · USPTO record | In force | USPTO record | |
| US 7,884,099 | Quinolone carboxylic acid-substituted rifamycin derivatives Formerly held In force · USPTO record | In force | USPTO record | |
| US 7,250,413 | C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes Formerly held Term ended Term ended Oct 18, 2025 · USPTO record | Term ended | Term ended Oct 18, 2025 | USPTO record |
| US 7,226,931 | (R/S) rifamycin derivatives, their preparations and pharmaceutical compositions Formerly held Term ended Term ended Sep 25, 2025 · USPTO record | Term ended | Term ended Sep 25, 2025 | USPTO record |
| US 7,229,996 | Rifamycin derivatives Formerly held Term ended Term ended Sep 25, 2025 · USPTO record | Term ended | Term ended Sep 25, 2025 | USPTO record |
| US 7,247,634 | Rifamycin derivatives effective against drug-resistant microbes Formerly held Term ended Term ended Aug 28, 2025 · USPTO record | Term ended | Term ended Aug 28, 2025 | USPTO record |
| US 7,238,694 | Rifamycin imino derivatives effective against drug-resistant microbes Formerly held Term ended Term ended Aug 23, 2025 · USPTO record | Term ended | Term ended Aug 23, 2025 | USPTO record |
| US 7,202,246 | Spiro-rifamycin derivatives targeting RNA polymerase Formerly held Term ended Term ended Jun 8, 2025 · USPTO record | Term ended | Term ended Jun 8, 2025 | USPTO record |
| US 7,265,107 | Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes Formerly held Lapsed on the fee record Ended Sep 4, 2019 · USPTO record | Lapsed on the fee record | Ended Sep 4, 2019 | USPTO record |
| US 7,256,187 | Rifamycin C-11 oxime derivatives effective against drug-resistant microbes Formerly held Lapsed on the fee record Ended Aug 14, 2019 · USPTO record | Lapsed on the fee record | Ended Aug 14, 2019 | USPTO record |